{"id":"NCT04553068","sponsor":"Evofem Inc.","briefTitle":"Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection","officialTitle":"Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-15","primaryCompletion":"2022-07-28","completion":"2022-07-28","firstPosted":"2020-09-17","resultsPosted":"2024-01-30","lastUpdate":"2024-01-30"},"enrollment":1892,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Sexually Transmitted Diseases","Gonorrhea","Chlamydia"],"interventions":[{"type":"DRUG","name":"EVO100","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"EVO100 gel","type":"EXPERIMENTAL"},{"label":"Placebo gel","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection","primaryOutcome":{"measure":"Percentage of Study Successes in the EVO100 and Placebo Treatment Groups","timeFrame":"16 weeks","effectByArm":[{"arm":"EVO100 Gel","deltaMin":684,"sd":null},{"arm":"Placebo Gel","deltaMin":696,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":98,"countries":["United States"]},"refs":{"pmids":["35418329"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":926},"commonTop":["vaginal discharge"]}}